Avacta Group PLC has announced the availability of its Annual Report and Accounts for the year ended 31 December 2023 and the Notice of the 2024 Annual General Meeting (AGM) on its website. The AGM is scheduled to be held on Wednesday, 26 June 2024 at Glaziers Hall, London. Shareholders have the right to attend the AGM, and beneficial shareholders may also be permitted to attend in person at the discretion of the chair. Pre-registration is recommended due to limited venue capacity.

Registered shareholders attending in person or by proxy will be able to vote on the day. The Company will provide a business update following the AGM, which will be recorded and uploaded on the Company's website for shareholders who are unable to attend in person. Shareholders are encouraged to pre-register their interest and prove their shareholding by emailing ICR Consilium by Friday, 21 June 2024.

Avacta Group plc is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. Avacta Therapeutics, its clinical stage oncology biotech division, is developing novel, highly targeted cancer drugs. Avacta Diagnostics aims to support healthcare professionals and broaden access to diagnostics. The company has two proprietary platforms, pre|CISION™ and Affimer®, which are utilized for developing targeted cancer drugs.

For further information, shareholders can contact Avacta Group plc or its appointed brokers.